Literature DB >> 28267657

Preoperative radiotherapy in breast cancer patients: 32 years of follow-up.

F G Riet1, F Fayard2, R Arriagada3, M A Santos4, C Bourgier5, M Ferchiou6, S Heymann7, S Delaloge8, C Mazouni9, A Dunant2, S Rivera7.   

Abstract

This study evaluates the long-term outcomes of a retrospective cohort of breast cancer (BC) patients who had received curatively intended premastectomy radiation therapy (RT). We analysed locoregional control, disease-free survival (DFS) and overall survival (OS), pathological complete remission (pCR), predictors thereof, and immediate safety. The series consisted of 187 patients with a median age of 49 years [43-60] and T2-T4 or N2 tumours. Between 1970 and 1984, they had received slightly hypofractionated RT to the whole breast, ipsilateral supraclavicular fossa and axilla ± the internal mammary chain (45-55 Gy/18 fractions of 2.5 Gy/34 days) systematically followed by a modified radical mastectomy with an axillary dissection. No other preoperative treatment was given. Among the 166 centrally reviewed tumour biopsy specimens, 22% had a triple-negative (TN) phenotype, 17% were HER2 3 + or amplified and 61% were ER+. The median follow-up was 32 years [23-35]. The 25-year locoregional control rate was 89% [93%-82%] and the 25-year DFS and OS rates were identical, 30% [24%-37%]. A pCR in the tumour and lymph nodes had been achieved in 18 among all patients (10%), but in 26% with TN disease. In the multivariate analysis, the TN status was the only predictive factor of pCR (OR = 5.49, 95% confidence interval [CI] 1.87-16.1, p = 0.002). Also, the pN status (HR = 1.69, [1.28-2.22], p = 0.0002) and TN subtype (HR = 1.80, [1.00-3.26], p = 0.05) exerted a significant prognostic impact on OS. The postoperative complication rate (grade >2) was 19% with 4.3% of localized skin necrosis. Preoperative RT followed by radical surgery is feasible and associated with good long-term locoregional control.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Hypofractionated radiation therapy; Pathological complete response; Preoperative radiation therapy; Triple-negative tumours

Mesh:

Substances:

Year:  2017        PMID: 28267657     DOI: 10.1016/j.ejca.2017.01.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

Review 1.  Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer.

Authors:  Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi
Journal:  Nat Rev Clin Oncol       Date:  2021-11-24       Impact factor: 66.675

2.  Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients.

Authors:  Hans Van Hulle; Vincent Vakaet; Giselle Post; Annick Van Greveling; Chris Monten; An Hendrix; Koen Van de Vijver; Jo Van Dorpe; Pieter De Visschere; Geert Braems; Katrien Vandecasteele; Hannelore Denys; Wilfried De Neve; Liv Veldeman
Journal:  Pilot Feasibility Stud       Date:  2020-10-10

3.  A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer.

Authors:  James Meehan; Mark Gray; Carlos Martínez-Pérez; Charlene Kay; Jimi C Wills; Ian H Kunkler; J Michael Dixon; Arran K Turnbull
Journal:  J Pers Med       Date:  2021-08-14

Review 4.  Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists.

Authors:  Alice Y Ho; Jean L Wright; Rachel C Blitzblau; Robert W Mutter; Dan G Duda; Larry Norton; Aditya Bardia; Laura Spring; Steven J Isakoff; Jonathan H Chen; Clemens Grassberger; Jennifer R Bellon; Sushil Beriwal; Atif J Khan; Corey Speers; Samantha A Dunn; Alastair Thompson; Cesar A Santa-Maria; Ian E Krop; Elizabeth Mittendorf; Tari A King; Gaorav P Gupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-05-14       Impact factor: 7.038

5.  Towards photon radiotherapy treatment planning with high Z nanoparticle radiosensitisation agents: the Relative Biological Effective Dose (RBED) framework.

Authors:  Jeremy M C Brown; Gerard G Hanna; Nathanael Lampe; Balder Villagomez-Bernabe; James R Nicol; Jonathan A Coulter; Fred J Currell
Journal:  Cancer Nanotechnol       Date:  2018-11-09

6.  Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer.

Authors:  Julie L Koenig; Margaret M Kozak; Aaron Sabolch; Kathleen Horst; Jillian Tsai; Irene L Wapnir; Erqi Pollom
Journal:  Cureus       Date:  2019-09-24

Review 7.  A systematic review of neo-adjuvant radiotherapy in the treatment of breast cancer.

Authors:  Muneer Ahmed; Felix Jozsa; Michael Douek
Journal:  Ecancermedicalscience       Date:  2021-01-22

8.  Impact of Preoperative vs Postoperative Radiotherapy on Overall Survival of Locally Advanced Breast Cancer Patients.

Authors:  Yujiao Deng; Hongtao Li; Yi Zheng; Zhen Zhai; Meng Wang; Shuai Lin; Yizhen Li; Bajin Wei; Peng Xu; Ying Wu; Xinyue Deng; Si Yang; Jun Lyu; Jingjing Hu; Huaying Dong; Zhijun Dai
Journal:  Front Oncol       Date:  2021-11-23       Impact factor: 6.244

9.  Predictive Factors of Long-Term Survival after Neoadjuvant Radiotherapy and Chemotherapy in High-Risk Breast Cancer.

Authors:  Jan Haussmann; Wilfried Budach; Carolin Nestle-Krämling; Sylvia Wollandt; Balint Tamaskovics; Stefanie Corradini; Edwin Bölke; David Krug; Tanja Fehm; Eugen Ruckhäberle; Werner Audretsch; Danny Jazmati; Christiane Matuschek
Journal:  Cancers (Basel)       Date:  2022-08-20       Impact factor: 6.575

Review 10.  Altered fractionation in radiation therapy for breast cancer in the elderly: are we moving forward?

Authors:  Valentina Pinzi; Laura Fariselli; Barbara Alicja Jereczek-Fossa
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.